Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IMUC .037?!! PENNYSTOCK TRADERS DONT KNOW THIS STOCK.
ONLY 41 MILLION O\S and 50 million A\S at .037???!! No f-ing way. $2.9 million cash on hand trading at a 1.7 million market cap???! No f-ing way. 19 INSTITUTIONS HOLD IMUC?!!! NO F-ING WAY. Was 23 cents 3 DAYS ago? STOP
IMUC was just delisted from the NYSE this morning. Big board traders ran for the hills. OVERKILL. This can run to 17 cents FAST folks.
IMUC was once $150. Median Analysts median target. I don't know but it's at 4 cents right now....shhh. OVERKILL. SNOOZE as you wish.
https://money.cnn.com/quote/forecast/forecast.html?symb=imuc
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +98,737.21% increase from the last price of 0.04.
$IMUC .037-on-the-ask!!! R-U-SEEING- THESE-BIDS?!WAS 23 CENTS 3 DAYS AGO. 50 MILLION A\S? WHALES SPLASHING. Jumping eachother w\bulky "make me richer" bids Was 23 cents DAYS ago watch NITE jump the bids w\endless 10k BID??
BUYOUT CANDIDATE. Once traded at $150. 9 cents coming.
$IMUC .037-on-the-ask!!! R-U-SEEING- THESE-BIDS?!WAS 23 CENTS 3 DAYS AGO. 50 MILLION A\S? WHALES SPLASHING. Jumping eachother w\bulky "make me richer" bids Was 23 cents DAYS ago watch NITE jump the bids w\endless 10k BID??
BUYOUT CANDIDATE. Once traded at $150
$IMUC .037-on-the-ask!!! WAS 23 CENTS 3 DAYS AGO. 50 MILLION A\S? WHALES SPLASHING. Jumping eachother w\bulky "make me richer" bids Was 23 cents DAYS ago watch NITE jump the bids w\endless 10k BID??
BUYOUT CANDIDATE. Once traded at $150
$IMUC .037-on-the-ask!!! WAS 23 CENTS 3 DAYS AGO. 50 MILLION A\S? WHALES SPLASHING. Jumping eachother w\bulky "make me richer" bids Was 23 cents DAYS ago watch NITE jump the bids w\endless 10k BID??
BUYOUT CANDIDATE. Once traded at $150
$IMUC .037??! Was once $150 on NYSE! Battered #biotech was once trading at $150 on the NYSE. Just got delisted yesterdayay so big board traders dumped her. INSTITUTIONS OWN 4% OF THE COMPANY! 19 instiS hold IMUC. Was at 23 cents 3 DAYS ago. These guys have $2.9 million cash on hand trading at a $1.7 million market cap??! ONLY 41 MILLION O\S! Overreaction the delisting was already built into the price days ago. Come to DADDY!!
$IMUC .037??! Was once $150 on NYSE! Battered #biotech was once trading at $150 on the NYSE. Just got delisted yesterdayay so big board traders dumped her. INSTITUTIONS OWN 4% OF THE COMPANY! 19 instiS hold IMUC. Was at 23 cents 3 DAYS ago. These guys have $2.9 million cash on hand trading at a $1.7 million market cap??! ONLY 41 MILLION O\S! Overreaction the delisting was already built into the price days ago. Come to DADDY!!
IMUC .037? Was 23 cents 3 DAYS ago. Held by 19 institutions, only 50 million A\S and it's at 037?! With the amount of shares HELD BY institutions there are DEFINITELY not enough shares down at this level. Crashed after hours because it got delisted from the NYSE. Fellas it's a gift.
$IMUC .037?!! PENNYSTOCK TRADERS DONT KNOW THIS STOCK.
ONLY 41 MILLION O\S and 50 million A\S at .037???!! No f-ing way. $2.9 million cash on hand trading at a 1.7 million market cap???! No f-ing way. 19 INSTITUTIONS HOLD IMUC?!!! NO F-ING WAY. Was 23 cents 3 DAYS ago? STOP
IMUC was just delisted from the NYSE this morning. Big board traders ran for the hills. OVERKILL. This can run to 17 cents FAST folks.
IMUC was once $150. Median Analysts median target. I don't know but it's at 4 cents right now....shhh. OVERKILL. SNOOZE as you wish.
https://money.cnn.com/quote/forecast/forecast.html?symb=imuc
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +98,737.21% increase from the last price of 0.04.
$IMUC .037?!! PENNYSTOCK TRADERS DONT KNOW THIS STOCK.
ONLY 41 MILLION O\S and 50 million A\S at .037???!! No f-ing way. $2.9 million cash on hand trading at a 1.7 million market cap???! No f-ing way. 19 INSTITUTIONS HOLD IMUC?!!! NO F-ING WAY. Was 23 cents 3 DAYS ago? STOP
IMUC was just delisted from the NYSE this morning. Big board traders ran for the hills. OVERKILL. This can run to 17 cents FAST folks.
IMUC was once $150. Median Analysts median target. I don't know but it's at 4 cents right now....shhh. OVERKILL. SNOOZE as you wish.
https://money.cnn.com/quote/forecast/forecast.html?symb=imuc
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +98,737.21% increase from the last price of 0.04.
$IMUC .045?!! PENNYSTOCK TRADERS DONT KNOW THIS STOCK. MONEY FLYING IN.
IMUC was just delisted from the NYSE this morning. Big board traders ran for the hills. OVERKILL. This can run to 17 cents FAST folks.
IMUC was once $150. Median Analysts median target. I don't know but it's at 4 cents right now....shhh. OVERKILL. SNOOZE as you wish.
https://money.cnn.com/quote/forecast/forecast.html?symb=imuc
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +98,737.21% increase from the last price of 0.04.
$IMUC .045?!! PENNYSTOCK TRADERS DONT KNOW THIS STOCK. MONEY FLYING IN.
IMUC was just delisted from the NYSE this morning. Big board traders ran for the hills. OVERKILL. This can run to 17 cents FAST folks.
IMUC was once $150. Median Analysts median target. I don't know but it's at 4 cents right now....shhh. OVERKILL. SNOOZE as you wish.
https://money.cnn.com/quote/forecast/forecast.html?symb=imuc
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +98,737.21% increase from the last price of 0.04.
$IMUC .045?!! PENNYSTOCK TRADERS DONT KNOW THIS STOCK. MONEY FLYING IN.
IMUC was just delisted from the NYSE this morning. Big board traders ran for the hills. OVERKILL. This can run to 17 cents FAST folks.
IMUC was once $150. Median Analysts median target. I don't know but it's at 4 cents right now....shhh. OVERKILL. SNOOZE as you wish.
https://money.cnn.com/quote/forecast/forecast.html?symb=imuc
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +98,737.21% increase from the last price of 0.04.
$IMUC .045?!! PENNYSTOCK TRADERS DONT KNOW THIS STOCK. MONEY FLYING IN.
IMUC was just delisted from the NYSE this morning. Big board traders ran for the hills. OVERKILL. This can run to 17 cents FAST folks.
IMUC was once $150. Median Analysts median target. I don't know but it's at 4 cents right now....shhh. OVERKILL. SNOOZE as you wish.
https://money.cnn.com/quote/forecast/forecast.html?symb=imuc
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +98,737.21% increase from the last price of 0.04.
$IMUC TRAIN LEAVING THE STATION .043 WAS once $150 on NYSE. OVERKILL
$IMUC .037??! Was once $150 on NYSE! Battered #biotech was once trading at $150 on the NYSE. Just got delisted today so big board traders dumped her. INSTITUTIONS OWN 4% OF THE COMPANY! These guys have $2 million cash on hand trading at a $1.8 million market cap??! ONLY 41 MILLION O\S! Overreaction the delisting was already built into the price days ago. Come to DADDY!!
$IMUC .037??! Was once $150 on NYSE! Battered #biotech was once trading at $150 on the NYSE. Just got delisted today so big board traders dumped her. INSTITUTIONS OWN 4% OF THE COMPANY! These guys have $2 million cash on hand trading at a $1.8 million market cap??! ONLY 41 MILLION O\S! Overreaction the delisting was already built into the price days ago. Come to DADDY!!
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 1 cent BEFORE its cancer patent was granted months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 2 cents BEFORE its cancer patent was granted 4 months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 1 cent BEFORE its cancer patent was granted months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 2 cents BEFORE its cancer patent was granted 4 months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX 006?!! A 1000% run would be an underachievement. Fell from 55 cents to below 1 cent BEFORE its cancer patent was granted months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. HUGE NEWS WEEKS AGO that went unnoticed. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 2 cents BEFORE its cancer patent was granted 4 months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX 006?!! A 1000% run would be an underachievement. Fell from 55 cents to below 1 cent BEFORE its cancer patent was granted months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. HUGE NEWS WEEKS AGO that went unnoticed. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 2 cents BEFORE its cancer patent was granted 4 months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX is EXTREMELY OVERSOLD here. Its trading as if it's a shell and that news and 8k filing should tell traders it's far from that. It was trading at 55 cents a little over a year ago! I'm accumulating. This is going to pop like PPC* & PNA*. Expect at LEAST a 1000% run in the next 6 month's at the most.
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 1 cent BEFORE its cancer patent was granted months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 2 cents BEFORE its cancer patent was granted 4 months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 1 cent BEFORE its cancer patent was granted months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$NSPX a 1000% run would be an underachievement. Fell from 55 cents to below 2 cents BEFORE its cancer patent was granted 4 months ago. Only 9 million O\S? Merger with a sophisticated biotech company Lewis and Clark last August. Too easy. $1 target.
What are the advantages of the merger with Lewis and Clark?
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX NSPX
$RETC 0037!!? DOWN 40% 52 WEEK HIGH 29 CENTS. FACT 7 MILLION ON THE BID ALL DAY YESTERDAY. LOOK at those massive bids NOW!
Here's the sweetest part 58% of shares HELD BY INSIDERS, I wonder why? Lock em and I'm loading them.
Why do insiders own 58% of the shares? Please give an INTELLIGENT explanation here. See you at 3 cents.
$RETC 0037!!? DOWN 40% 52 WEEK HIGH 29 CENTS. FACT 7 MILLION ON THE BID ALL DAY YESTERDAY. LOOK at those massive bids NOW!
Here's the sweetest part 58% of shares HELD BY INSIDERS, I wonder why? Lock em and I'm loading them.
Why do insiders own 58% of the shares? Please give an INTELLIGENT explanation here. See you at 3 cents.
RETC 005!!? 52 WEEK HIGH 29 CENTS. FACT 7 MILLION ON THE BID ALL DAY YESTERDAY FACT, L2 THIN FACT.
Here's the sweetest part 58% of shares HELD BY INSIDERS, I wonder why? Lock em and I'm loading them.
For all the critics can you please tell me why insiders own 58% of the shares? Please give an INTELLIGENT explanation here. See you at 3 cents.
RETC 005!!? 52 WEEK HIGH 29 CENTS. FACT 7 MILLION ON THE BID ALL DAY YESTERDAY FACT, L2 THIN FACT.
Here's the sweetest part 58% of shares HELD BY INSIDERS, I wonder why? Lock em and I'm loading them.
For all the critics can you please tell me why insiders own 58% of the shares? Please give an INTELLIGENT explanation here. See you at 3 cents.
RETC 52 WEEK HIGH 29 CENTS. FACT 7 MILLION ON THE BID ALL DAY YESTERDAY FACT, L2 THIN FACT.
Here's the sweetest part 58% of shares HELD BY INSIDERS, I wonder why? Lock em and I'm loading them.
For all the critics can you please tell me why insiders own 58% of the shares? Please give an INTELLIGENT explanation here. See you at 3 cents.
RETC .. MAXM has nothing. Every time he's touched he moves. I mean wow now they are saying MAXM and CDEL are tag teaming and want people to believe them? Diluting through 2 mms at the same time? WOW. Traders will say anything. Watch her close above 0073
RETC 52 WEEK HIGH 29 CENTS. LOOK AT THAT L2 thin as tissue. Added again. Thank you!
RETC .005 52WEEKHIGH 29 CENTS! UNKBOWN BUT NOT FOR LONG. FEED ME
RETC .005 52WEEKHIGH 29 CENTS! UNKBOWN BUT NOT FOR LONG. FEED ME
RETC TINY VOLUME drop. Added and on bids at all levels. Too easy. Stop sleeping
$RETC 006 ON THE ASK!! LOADING THIS DIP WITH BOTH HANDS. 52 week high 29 cents. Ding ding ding!
$RETC 006 ON THE ASK!! LOADING THIS DIP WITH BOTH HANDS. 52 week high 29 cents. Ding ding ding!
RETC finally eyes on this. Get your fork and knives out. The cat is out the bag. RETC traded at 29 cents less than a year ago, it's definitely hitting pennies. STRONG CLOSE. EEEEEAT!
RETC LETS GET TO TGAT 52 WEEK HIGH. THE TRAIN IS LEAVING
$RETC .0059 WATCH HER GAP AND RUN tomorrow. Look at the tiny bidwhacks all day today. Feeble attempts to bring her down.
RETC beautiful day. We haven't even come close to begun yet. GAPPERRR! This is going to be fun.